CollPlant Biotechnologies Ltd. (CLGN) 10-Year Financial Performance & Capital Metrics

CLGN • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutCollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.Show more

Revenue $515K -95.3%
EBITDA -$16M -152.9%
Net Income -$17M -136.6%
EPS (Diluted) -1.45 -133.9%
Gross Margin -417.09% -681.1%
EBITDA Margin -3148.16% -5282.3%
Operating Margin -3349.71% -4786.8%
Net Margin -3225.05% -4935.4%
ROE -79.46% -243.1%
ROIC -273.48% -151.5%
Debt/Equity 0.23 +105.3%
Interest Coverage -1014.76 -35.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Sales declining 26.0% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-25.98%

3Y-67.95%

TTM280.77%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM33.33%

ROCE

10Y Avg-99.58%

5Y Avg-42.78%

3Y Avg-46.07%

Latest-74.01%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	75.91K	479.92K	4.79M	2.32M	6.14M	15.64M	299K	10.96M	515K
Revenue Growth %	-	-	5.32%	8.98%	-0.52%	1.65%	1.55%	-0.98%	35.65%	-0.95%
Cost of Goods Sold+	202.82K	225.07K	306.09K	1.9M	2.27M	3.46M	2M	1.48M	3.09M	2.66M
COGS % of Revenue	-	2.96%	0.64%	0.4%	0.98%	0.56%	0.13%	4.94%	0.28%	5.17%
Gross Profit+	-202.82K	-149.01K	157.63K	3.11M	52K	2.68M	13.64M	-1.18M	7.87M	-2.15M
Gross Margin %	-	-1.96%	0.33%	0.65%	0.02%	0.44%	0.87%	-3.94%	0.72%	-4.17%
Gross Profit Growth %	0.1%	0.27%	2.06%	18.74%	-0.98%	50.52%	4.09%	-1.09%	7.68%	-1.27%
Operating Expenses+	7.49M	10.26M	6.72M	7.68M	7.71M	8.28M	13.57M	15.92M	15.38M	15.1M
OpEx % of Revenue	-	135.15%	14%	1.6%	3.33%	1.35%	0.87%	53.24%	1.4%	29.33%
Selling, General & Admin	1.78M	2.87M	2.3M	3.7M	3.62M	4.62M	5.94M	5.67M	4.89M	4.59M
SG&A % of Revenue	-	37.78%	4.78%	0.77%	1.56%	0.75%	0.38%	18.95%	0.45%	8.91%
Research & Development	3.04M	4.36M	4.05M	5.16M	4.41M	3.66M	7.63M	10.26M	10.48M	10.52M
R&D % of Revenue	-	57.5%	8.43%	1.08%	1.9%	0.6%	0.49%	34.3%	0.96%	20.42%
Other Operating Expenses	6.4K	9.88K	13.52K	21.51K	33K	0	0	0	0	0
Operating Income+	-4.82M	-7.16M	-5.97M	-4.07M	-7.63M	-5.6M	65K	-17.1M	-7.51M	-17.25M
Operating Margin %	-	-94.33%	-12.44%	-0.85%	-3.29%	-0.91%	0%	-57.18%	-0.69%	-33.5%
Operating Income Growth %	-0.38%	-0.49%	0.17%	0.32%	-0.88%	0.27%	1.01%	-264.03%	0.56%	-1.3%
EBITDA+	-4.62M	-6.94M	-5.68M	-3.72M	-7.09M	-4.94M	838K	-16.02M	-6.41M	-16.21M
EBITDA Margin %	-	-91.37%	-11.83%	-0.78%	-3.06%	-0.8%	0.05%	-53.58%	-0.58%	-31.48%
EBITDA Growth %	-0.4%	-0.5%	0.18%	0.34%	-0.9%	0.3%	1.17%	-20.12%	0.6%	-1.53%
D&A (Non-Cash Add-back)	201.86K	225.07K	291.63K	342K	539K	660K	773K	1.08M	1.1M	1.04M
EBIT	-4.8M	-7.25M	-5.7M	-6.22M	-11.09M	-5.74M	274K	-16.89M	-7.01M	-16.59M
Net Interest Income+	0	-15.89K	-105.64K	-26K	-73K	-34K	182K	287K	778K	721K
Interest Income	0	0	0	0	0	0	219K	321K	788K	738K
Interest Expense	0	15.89K	105.64K	26K	73K	34K	37K	34K	10K	17K
Other Income/Expense	50.87K	-101.99K	-94K	-2M	-3.53M	-175K	172K	172K	493K	642K
Pretax Income+	-4.78M	-7.25M	-6.01M	-3.69M	-11.16M	-5.77M	237K	-16.93M	-7.02M	-16.61M
Pretax Margin %	-	-95.52%	-12.52%	-0.77%	-4.82%	-0.94%	0.02%	-56.61%	-0.64%	-32.25%
Income Tax+	63.85K	0	28.44K	2.96M	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.97%	1.69%	1%	1%	1%	1%	1%	1%
Net Income+	-4.8M	-7.27M	-5.8M	-6.25M	-11.16M	-5.77M	237K	-16.93M	-7.02M	-16.61M
Net Margin %	-	-95.72%	-12.1%	-1.31%	-4.82%	-0.94%	0.02%	-56.61%	-0.64%	-32.25%
Net Income Growth %	-0.32%	-0.51%	0.2%	-0.08%	-0.79%	0.48%	1.04%	-72.41%	0.59%	-1.37%
Net Income (Continuing)	-4.8M	-7.25M	-6.05M	-6.25M	-11.16M	-5.77M	237K	-16.93M	-7.02M	-16.61M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.83	-3.60	-2.27	-1.43	-2.95	-0.84	0.03	-1.52	-0.62	-1.45
EPS Growth %	-0.36%	-0.27%	0.37%	0.37%	-1.06%	0.72%	1.04%	-45.44%	0.59%	-1.34%
EPS (Basic)	-2.83	-3.60	-2.27	-1.43	-2.95	-0.84	0.04	-1.52	-0.62	-1.45
Diluted Shares Outstanding	1.69M	2.01M	2.66M	4.38M	4.99M	6.89M	11.97M	11.03M	11.39M	11.45M
Basic Shares Outstanding	1.69M	2.01M	2.66M	4.38M	4.99M	6.89M	9.97M	11.03M	11.39M	11.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.19M	2.1M	6.45M	7.14M	5.04M	5.68M	45.09M	31.66M	28.02M	13.18M
Cash & Short-Term Investments	1.36M	987.11K	5.13M	5.33M	3.79M	3.33M	43.3M	29.65M	26.67M	11.91M
Cash Only	1.36M	987.11K	5.13M	5.33M	3.79M	3.33M	13.15M	29.65M	26.67M	11.91M
Short-Term Investments	0	0	0	0	0	0	30.15M	0	0	0
Accounts Receivable	468.53K	949.93K	102.02K	516K	79K	830K	270K	9K	393K	583K
Days Sales Outstanding	-	4.57K	77.59	39.33	12.44	49.36	6.3	10.99	13.09	413.19
Inventory	0	126.61K	201.4K	810.37K	888K	1.26M	1.08M	1.43M	714K	440K
Days Inventory Outstanding	-	205.32	240.17	155.51	143.04	133.21	196.79	353.62	84.26	60.31
Other Current Assets	0	0	525.21K	380.01K	136K	93K	437K	566K	241K	248K
Total Non-Current Assets+	1.27M	1.65M	1.62M	1.91M	5.71M	5.17M	6.14M	6.11M	6.1M	5.53M
Property, Plant & Equipment	669.12K	1.04M	1.03M	1.4M	5.54M	4.9M	5.68M	5.68M	5.86M	5.28M
Fixed Asset Turnover	-	0.07x	0.47x	3.42x	0.42x	1.25x	2.75x	0.05x	1.87x	0.10x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	440.87K	424.01K	418.35K	338.01K	0	82K	243K	245K	188K	131K
Long-Term Investments	163.97K	188.38K	171.39K	173K	168K	181K	0	188K	57K	118K
Other Non-Current Assets	163.44K	188.48K	171.19K	172.06K	0	181K	426K	188K	0	0
Total Assets+	3.47M	3.75M	8.07M	9.05M	10.75M	10.84M	51.22M	37.77M	34.13M	18.71M
Asset Turnover	-	0.02x	0.06x	0.53x	0.22x	0.57x	0.31x	0.01x	0.32x	0.03x
Asset Growth %	-0.2%	0.08%	1.15%	0.12%	0.19%	0.01%	3.73%	-0.26%	-0.1%	-0.45%
Total Current Liabilities+	960.64K	1.77M	1.42M	2.23M	3.46M	3.39M	3.01M	3.1M	3.25M	2.97M
Accounts Payable	639.4K	1.35M	840.72K	622K	833K	798K	1.03M	1.13M	980K	870K
Days Payables Outstanding	1.15K	2.19K	1K	119.36	134.18	84.23	188.23	280.18	115.65	119.25
Short-Term Debt	0	0	0	22K	24K	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	965.43K	942K	207K	32K	0	0	0
Other Current Liabilities	133.72K	218.9K	574.29K	44.45K	245K	1.27M	566K	499K	1.54M	1.19M
Current Ratio	2.28x	1.19x	4.56x	3.19x	1.46x	1.68x	14.96x	10.20x	8.62x	4.44x
Quick Ratio	2.28x	1.11x	4.42x	2.83x	1.20x	1.30x	14.60x	9.74x	8.40x	4.29x
Cash Conversion Cycle	-	2.59K	-684.77	75.48	21.3	98.34	14.86	84.43	-18.3	354.26
Total Non-Current Liabilities+	0	641.35K	4.04M	2.05M	3.21M	2.98M	3.09M	2.38M	2.54M	2.27M
Long-Term Debt	0	0	3.64M	22K	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	3.14M	2.95M	3.09M	2.38M	2.54M	2.27M
Deferred Tax Liabilities	0	0	0	742.66K	0	0	0	0	0	0
Other Non-Current Liabilities	0	641.35K	404.25K	1.08M	68K	28K	0	0	0	0
Total Liabilities	960.64K	2.41M	5.46M	4.29M	6.66M	6.36M	6.1M	5.49M	5.79M	5.25M
Total Debt+	0	0	3.64M	44.61K	3.62M	3.39M	3.61M	2.91M	3.16M	3.08M
Net Debt	-1.36M	-987.11K	-1.49M	-5.28M	-173K	55K	-9.54M	-26.74M	-23.52M	-8.83M
Debt / Equity	-	-	1.39x	0.01x	0.89x	0.76x	0.08x	0.09x	0.11x	0.23x
Debt / EBITDA	-	-	-	-	-	-	4.31x	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-11.38x	-	-	-
Interest Coverage	-	-450.65x	-56.52x	-156.37x	-104.53x	-164.68x	1.76x	-502.85x	-751.20x	-1014.76x
Total Equity+	2.51M	1.34M	2.61M	4.76M	4.09M	4.48M	45.12M	32.28M	28.34M	13.46M
Equity Growth %	-0.32%	-0.46%	0.95%	0.82%	-0.14%	0.1%	9.08%	-0.28%	-0.12%	-0.52%
Book Value per Share	1.48	0.67	0.98	1.09	0.82	0.65	3.77	2.93	2.49	1.18
Total Shareholders' Equity	2.51M	1.34M	2.61M	4.76M	4.09M	4.48M	45.12M	32.28M	28.34M	13.46M
Common Stock	682.69K	833.72K	1.44M	1.52M	2.37M	2.93M	4.66M	4.87M	4.98M	4.98M
Retained Earnings	-34.22M	-41.05M	-50.17M	-49.03M	-67.26M	-73.03M	-72.8M	-89.72M	-96.74M	-113.35M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.99M	-2.22M	-2.7M	-2.84M	-969K	-969K	-969K	-969K	-969K	-969K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.72M	-5.02M	-4.97M	-1.22M	-5.7M	-4.45M	2.5M	-13.7M	-2.76M	-14.09M
Operating CF Margin %	-	-66.18%	-10.35%	-0.25%	-2.46%	-0.73%	0.16%	-45.81%	-0.25%	-27.37%
Operating CF Growth %	-0.12%	-0.35%	0.01%	0.75%	-3.69%	0.22%	1.56%	-6.48%	0.8%	-4.1%
Net Income	-4.79M	-7.24M	-6.05M	-6.25M	-11.16M	-5.77M	237K	-16.93M	-7.02M	-16.61M
Depreciation & Amortization	202.23K	224.25K	230K	342K	539K	660K	773K	1.08M	1.1M	1.04M
Stock-Based Compensation	1.05M	927.12K	956K	1.43M	1.13M	1.67M	1.62M	2.17M	1.94M	1.72M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	192.22K	691.19K	-502K	4.03M	2.39M	-870K	-284K	588K	216K	21K
Working Capital Changes	-375.98K	372.98K	401K	-773K	1.41M	-141K	155K	-611K	1M	-262K
Change in Receivables	-434.49K	-141.2K	-38K	-439K	437K	-751K	560K	261K	9K	-150K
Change in Inventory	0	-126.4K	-59K	-653K	-74K	-374K	181K	-312K	749K	280K
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-356.47K	-127.7K	-127K	-832K	-1.46M	-519K	-31.56M	28.92M	-1.16M	-539K
Capital Expenditures	-356.47K	-127.7K	-127K	-832K	-1.49M	-437K	-1.43M	-1.27M	-954K	-483K
CapEx % of Revenue	-	1.68%	0.26%	0.17%	0.64%	0.07%	0.09%	4.26%	0.09%	0.94%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	30K	-82K	-30.13M	30.2M	-202K	-56K
Cash from Financing+	2.58M	4.8M	9.11M	2.75M	5.41M	4.46M	38.76M	1.87M	1.11M	9K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.58M	4.8M	9.11M	2.71M	5.43M	4.49M	38.76M	1.87M	1.11M	9K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.08M	-5.15M	-5.09M	-2.05M	-7.19M	-4.89M	1.07M	-14.97M	-3.72M	-14.58M
FCF Margin %	-	-67.87%	-10.61%	-0.43%	-3.1%	-0.8%	0.07%	-50.07%	-0.34%	-28.3%
FCF Growth %	-0.19%	-0.26%	0.01%	0.6%	-2.51%	0.32%	1.22%	-14.95%	0.75%	-2.92%
FCF per Share	-2.41	-2.56	-1.91	-0.47	-1.44	-0.71	0.09	-1.36	-0.33	-1.27
FCF Conversion (FCF/Net Income)	0.78x	0.69x	0.86x	0.19x	0.51x	0.77x	10.55x	0.81x	0.39x	0.85x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	31K	8K	62K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-155.34%	-377.8%	-293.56%	-169.51%	-252.36%	-134.83%	0.96%	-43.73%	-23.16%	-79.46%
Return on Invested Capital (ROIC)	-365.6%	-717.35%	-606.04%	-1016.06%	-337.49%	-99.43%	0.24%	-62.37%	-108.72%	-273.48%
Gross Margin	-	-196.29%	32.85%	64.99%	2.24%	43.65%	87.18%	-393.65%	71.78%	-417.09%
Net Margin	-	-9571.91%	-1209.56%	-130.5%	-481.62%	-94.09%	1.52%	-5660.54%	-64.05%	-3225.05%
Debt / Equity	-	-	1.39x	0.01x	0.89x	0.76x	0.08x	0.09x	0.11x	0.23x
Interest Coverage	-	-450.65x	-56.52x	-156.37x	-104.53x	-164.68x	1.76x	-502.85x	-751.20x	-1014.76x
FCF Conversion	0.78x	0.69x	0.86x	0.19x	0.51x	0.77x	10.55x	0.81x	0.39x	0.85x
Revenue Growth	-	-	532.21%	897.75%	-51.59%	164.75%	154.86%	-98.09%	3565.22%	-95.3%

Revenue by Geography

	2017	2018	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	15.01M	174K	10.84M	484K
UNITED STATES Growth	-	-	-	-	-98.84%	6129.31%	-95.53%
ISRAEL	-	-	-	-	-	5K	31K
ISRAEL Growth	-	-	-	-	-	-	520.00%
CANADA	-	-	-	-	-	87K	-
CANADA Growth	-	-	-	-	-	-	-
Europe	-	-	369K	628K	125K	-	-
Europe Growth	-	-	-	70.19%	-80.10%	-	-
TotalMember	-	-	6.14M	15.64M	-	-	-
TotalMember Growth	-	-	-	154.86%	-	-	-
United States And Canada	-	17.51M	-	-	-	-	-
United States And Canada Growth	-	-	-	-	-	-	-
Europe Country	-	523K	-	-	-	-	-
Europe Country Growth	-	-	-	-	-	-	-
European	866K	-	-	-	-	-	-
European Growth	-	-	-	-	-	-	-
United Satetes And Canada	802K	-	-	-	-	-	-
United Satetes And Canada Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

CollPlant Biotechnologies Ltd. (CLGN) reported $2.5M in revenue for fiscal year 2024.

CollPlant Biotechnologies Ltd. (CLGN) saw revenue decline by 95.3% over the past year.

CollPlant Biotechnologies Ltd. (CLGN) reported a net loss of $12.2M for fiscal year 2024.

Dividend & Returns

CollPlant Biotechnologies Ltd. (CLGN) has a return on equity (ROE) of -79.5%. Negative ROE indicates the company is unprofitable.

CollPlant Biotechnologies Ltd. (CLGN) had negative free cash flow of $10.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

CollPlant Biotechnologies Ltd. (CLGN) 10-Year Financial Performance & Capital Metrics

CLGN • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $515K -95.3%
EBITDA -$16M -152.9%
Net Income -$17M -136.6%
EPS (Diluted) -1.45 -133.9%
Gross Margin -417.09% -681.1%
EBITDA Margin -3148.16% -5282.3%
Operating Margin -3349.71% -4786.8%
Net Margin -3225.05% -4935.4%
ROE -79.46% -243.1%
ROIC -273.48% -151.5%
Debt/Equity 0.23 +105.3%
Interest Coverage -1014.76 -35.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Sales declining 26.0% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-25.98%

3Y-67.95%

TTM280.77%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM33.33%

ROCE

10Y Avg-99.58%

5Y Avg-42.78%

3Y Avg-46.07%

Latest-74.01%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	75.91K	479.92K	4.79M	2.32M	6.14M	15.64M	299K	10.96M	515K
Revenue Growth %	-	-	5.32%	8.98%	-0.52%	1.65%	1.55%	-0.98%	35.65%	-0.95%
Cost of Goods Sold+	202.82K	225.07K	306.09K	1.9M	2.27M	3.46M	2M	1.48M	3.09M	2.66M
COGS % of Revenue	-	2.96%	0.64%	0.4%	0.98%	0.56%	0.13%	4.94%	0.28%	5.17%
Gross Profit+	-202.82K	-149.01K	157.63K	3.11M	52K	2.68M	13.64M	-1.18M	7.87M	-2.15M
Gross Margin %	-	-1.96%	0.33%	0.65%	0.02%	0.44%	0.87%	-3.94%	0.72%	-4.17%
Gross Profit Growth %	0.1%	0.27%	2.06%	18.74%	-0.98%	50.52%	4.09%	-1.09%	7.68%	-1.27%
Operating Expenses+	7.49M	10.26M	6.72M	7.68M	7.71M	8.28M	13.57M	15.92M	15.38M	15.1M
OpEx % of Revenue	-	135.15%	14%	1.6%	3.33%	1.35%	0.87%	53.24%	1.4%	29.33%
Selling, General & Admin	1.78M	2.87M	2.3M	3.7M	3.62M	4.62M	5.94M	5.67M	4.89M	4.59M
SG&A % of Revenue	-	37.78%	4.78%	0.77%	1.56%	0.75%	0.38%	18.95%	0.45%	8.91%
Research & Development	3.04M	4.36M	4.05M	5.16M	4.41M	3.66M	7.63M	10.26M	10.48M	10.52M
R&D % of Revenue	-	57.5%	8.43%	1.08%	1.9%	0.6%	0.49%	34.3%	0.96%	20.42%
Other Operating Expenses	6.4K	9.88K	13.52K	21.51K	33K	0	0	0	0	0
Operating Income+	-4.82M	-7.16M	-5.97M	-4.07M	-7.63M	-5.6M	65K	-17.1M	-7.51M	-17.25M
Operating Margin %	-	-94.33%	-12.44%	-0.85%	-3.29%	-0.91%	0%	-57.18%	-0.69%	-33.5%
Operating Income Growth %	-0.38%	-0.49%	0.17%	0.32%	-0.88%	0.27%	1.01%	-264.03%	0.56%	-1.3%
EBITDA+	-4.62M	-6.94M	-5.68M	-3.72M	-7.09M	-4.94M	838K	-16.02M	-6.41M	-16.21M
EBITDA Margin %	-	-91.37%	-11.83%	-0.78%	-3.06%	-0.8%	0.05%	-53.58%	-0.58%	-31.48%
EBITDA Growth %	-0.4%	-0.5%	0.18%	0.34%	-0.9%	0.3%	1.17%	-20.12%	0.6%	-1.53%
D&A (Non-Cash Add-back)	201.86K	225.07K	291.63K	342K	539K	660K	773K	1.08M	1.1M	1.04M
EBIT	-4.8M	-7.25M	-5.7M	-6.22M	-11.09M	-5.74M	274K	-16.89M	-7.01M	-16.59M
Net Interest Income+	0	-15.89K	-105.64K	-26K	-73K	-34K	182K	287K	778K	721K
Interest Income	0	0	0	0	0	0	219K	321K	788K	738K
Interest Expense	0	15.89K	105.64K	26K	73K	34K	37K	34K	10K	17K
Other Income/Expense	50.87K	-101.99K	-94K	-2M	-3.53M	-175K	172K	172K	493K	642K
Pretax Income+	-4.78M	-7.25M	-6.01M	-3.69M	-11.16M	-5.77M	237K	-16.93M	-7.02M	-16.61M
Pretax Margin %	-	-95.52%	-12.52%	-0.77%	-4.82%	-0.94%	0.02%	-56.61%	-0.64%	-32.25%
Income Tax+	63.85K	0	28.44K	2.96M	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.97%	1.69%	1%	1%	1%	1%	1%	1%
Net Income+	-4.8M	-7.27M	-5.8M	-6.25M	-11.16M	-5.77M	237K	-16.93M	-7.02M	-16.61M
Net Margin %	-	-95.72%	-12.1%	-1.31%	-4.82%	-0.94%	0.02%	-56.61%	-0.64%	-32.25%
Net Income Growth %	-0.32%	-0.51%	0.2%	-0.08%	-0.79%	0.48%	1.04%	-72.41%	0.59%	-1.37%
Net Income (Continuing)	-4.8M	-7.25M	-6.05M	-6.25M	-11.16M	-5.77M	237K	-16.93M	-7.02M	-16.61M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.83	-3.60	-2.27	-1.43	-2.95	-0.84	0.03	-1.52	-0.62	-1.45
EPS Growth %	-0.36%	-0.27%	0.37%	0.37%	-1.06%	0.72%	1.04%	-45.44%	0.59%	-1.34%
EPS (Basic)	-2.83	-3.60	-2.27	-1.43	-2.95	-0.84	0.04	-1.52	-0.62	-1.45
Diluted Shares Outstanding	1.69M	2.01M	2.66M	4.38M	4.99M	6.89M	11.97M	11.03M	11.39M	11.45M
Basic Shares Outstanding	1.69M	2.01M	2.66M	4.38M	4.99M	6.89M	9.97M	11.03M	11.39M	11.45M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.19M	2.1M	6.45M	7.14M	5.04M	5.68M	45.09M	31.66M	28.02M	13.18M
Cash & Short-Term Investments	1.36M	987.11K	5.13M	5.33M	3.79M	3.33M	43.3M	29.65M	26.67M	11.91M
Cash Only	1.36M	987.11K	5.13M	5.33M	3.79M	3.33M	13.15M	29.65M	26.67M	11.91M
Short-Term Investments	0	0	0	0	0	0	30.15M	0	0	0
Accounts Receivable	468.53K	949.93K	102.02K	516K	79K	830K	270K	9K	393K	583K
Days Sales Outstanding	-	4.57K	77.59	39.33	12.44	49.36	6.3	10.99	13.09	413.19
Inventory	0	126.61K	201.4K	810.37K	888K	1.26M	1.08M	1.43M	714K	440K
Days Inventory Outstanding	-	205.32	240.17	155.51	143.04	133.21	196.79	353.62	84.26	60.31
Other Current Assets	0	0	525.21K	380.01K	136K	93K	437K	566K	241K	248K
Total Non-Current Assets+	1.27M	1.65M	1.62M	1.91M	5.71M	5.17M	6.14M	6.11M	6.1M	5.53M
Property, Plant & Equipment	669.12K	1.04M	1.03M	1.4M	5.54M	4.9M	5.68M	5.68M	5.86M	5.28M
Fixed Asset Turnover	-	0.07x	0.47x	3.42x	0.42x	1.25x	2.75x	0.05x	1.87x	0.10x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	440.87K	424.01K	418.35K	338.01K	0	82K	243K	245K	188K	131K
Long-Term Investments	163.97K	188.38K	171.39K	173K	168K	181K	0	188K	57K	118K
Other Non-Current Assets	163.44K	188.48K	171.19K	172.06K	0	181K	426K	188K	0	0
Total Assets+	3.47M	3.75M	8.07M	9.05M	10.75M	10.84M	51.22M	37.77M	34.13M	18.71M
Asset Turnover	-	0.02x	0.06x	0.53x	0.22x	0.57x	0.31x	0.01x	0.32x	0.03x
Asset Growth %	-0.2%	0.08%	1.15%	0.12%	0.19%	0.01%	3.73%	-0.26%	-0.1%	-0.45%
Total Current Liabilities+	960.64K	1.77M	1.42M	2.23M	3.46M	3.39M	3.01M	3.1M	3.25M	2.97M
Accounts Payable	639.4K	1.35M	840.72K	622K	833K	798K	1.03M	1.13M	980K	870K
Days Payables Outstanding	1.15K	2.19K	1K	119.36	134.18	84.23	188.23	280.18	115.65	119.25
Short-Term Debt	0	0	0	22K	24K	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	965.43K	942K	207K	32K	0	0	0
Other Current Liabilities	133.72K	218.9K	574.29K	44.45K	245K	1.27M	566K	499K	1.54M	1.19M
Current Ratio	2.28x	1.19x	4.56x	3.19x	1.46x	1.68x	14.96x	10.20x	8.62x	4.44x
Quick Ratio	2.28x	1.11x	4.42x	2.83x	1.20x	1.30x	14.60x	9.74x	8.40x	4.29x
Cash Conversion Cycle	-	2.59K	-684.77	75.48	21.3	98.34	14.86	84.43	-18.3	354.26
Total Non-Current Liabilities+	0	641.35K	4.04M	2.05M	3.21M	2.98M	3.09M	2.38M	2.54M	2.27M
Long-Term Debt	0	0	3.64M	22K	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	3.14M	2.95M	3.09M	2.38M	2.54M	2.27M
Deferred Tax Liabilities	0	0	0	742.66K	0	0	0	0	0	0
Other Non-Current Liabilities	0	641.35K	404.25K	1.08M	68K	28K	0	0	0	0
Total Liabilities	960.64K	2.41M	5.46M	4.29M	6.66M	6.36M	6.1M	5.49M	5.79M	5.25M
Total Debt+	0	0	3.64M	44.61K	3.62M	3.39M	3.61M	2.91M	3.16M	3.08M
Net Debt	-1.36M	-987.11K	-1.49M	-5.28M	-173K	55K	-9.54M	-26.74M	-23.52M	-8.83M
Debt / Equity	-	-	1.39x	0.01x	0.89x	0.76x	0.08x	0.09x	0.11x	0.23x
Debt / EBITDA	-	-	-	-	-	-	4.31x	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-11.38x	-	-	-
Interest Coverage	-	-450.65x	-56.52x	-156.37x	-104.53x	-164.68x	1.76x	-502.85x	-751.20x	-1014.76x
Total Equity+	2.51M	1.34M	2.61M	4.76M	4.09M	4.48M	45.12M	32.28M	28.34M	13.46M
Equity Growth %	-0.32%	-0.46%	0.95%	0.82%	-0.14%	0.1%	9.08%	-0.28%	-0.12%	-0.52%
Book Value per Share	1.48	0.67	0.98	1.09	0.82	0.65	3.77	2.93	2.49	1.18
Total Shareholders' Equity	2.51M	1.34M	2.61M	4.76M	4.09M	4.48M	45.12M	32.28M	28.34M	13.46M
Common Stock	682.69K	833.72K	1.44M	1.52M	2.37M	2.93M	4.66M	4.87M	4.98M	4.98M
Retained Earnings	-34.22M	-41.05M	-50.17M	-49.03M	-67.26M	-73.03M	-72.8M	-89.72M	-96.74M	-113.35M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.99M	-2.22M	-2.7M	-2.84M	-969K	-969K	-969K	-969K	-969K	-969K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.72M	-5.02M	-4.97M	-1.22M	-5.7M	-4.45M	2.5M	-13.7M	-2.76M	-14.09M
Operating CF Margin %	-	-66.18%	-10.35%	-0.25%	-2.46%	-0.73%	0.16%	-45.81%	-0.25%	-27.37%
Operating CF Growth %	-0.12%	-0.35%	0.01%	0.75%	-3.69%	0.22%	1.56%	-6.48%	0.8%	-4.1%
Net Income	-4.79M	-7.24M	-6.05M	-6.25M	-11.16M	-5.77M	237K	-16.93M	-7.02M	-16.61M
Depreciation & Amortization	202.23K	224.25K	230K	342K	539K	660K	773K	1.08M	1.1M	1.04M
Stock-Based Compensation	1.05M	927.12K	956K	1.43M	1.13M	1.67M	1.62M	2.17M	1.94M	1.72M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	192.22K	691.19K	-502K	4.03M	2.39M	-870K	-284K	588K	216K	21K
Working Capital Changes	-375.98K	372.98K	401K	-773K	1.41M	-141K	155K	-611K	1M	-262K
Change in Receivables	-434.49K	-141.2K	-38K	-439K	437K	-751K	560K	261K	9K	-150K
Change in Inventory	0	-126.4K	-59K	-653K	-74K	-374K	181K	-312K	749K	280K
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-356.47K	-127.7K	-127K	-832K	-1.46M	-519K	-31.56M	28.92M	-1.16M	-539K
Capital Expenditures	-356.47K	-127.7K	-127K	-832K	-1.49M	-437K	-1.43M	-1.27M	-954K	-483K
CapEx % of Revenue	-	1.68%	0.26%	0.17%	0.64%	0.07%	0.09%	4.26%	0.09%	0.94%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	30K	-82K	-30.13M	30.2M	-202K	-56K
Cash from Financing+	2.58M	4.8M	9.11M	2.75M	5.41M	4.46M	38.76M	1.87M	1.11M	9K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.58M	4.8M	9.11M	2.71M	5.43M	4.49M	38.76M	1.87M	1.11M	9K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.08M	-5.15M	-5.09M	-2.05M	-7.19M	-4.89M	1.07M	-14.97M	-3.72M	-14.58M
FCF Margin %	-	-67.87%	-10.61%	-0.43%	-3.1%	-0.8%	0.07%	-50.07%	-0.34%	-28.3%
FCF Growth %	-0.19%	-0.26%	0.01%	0.6%	-2.51%	0.32%	1.22%	-14.95%	0.75%	-2.92%
FCF per Share	-2.41	-2.56	-1.91	-0.47	-1.44	-0.71	0.09	-1.36	-0.33	-1.27
FCF Conversion (FCF/Net Income)	0.78x	0.69x	0.86x	0.19x	0.51x	0.77x	10.55x	0.81x	0.39x	0.85x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	31K	8K	62K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-155.34%	-377.8%	-293.56%	-169.51%	-252.36%	-134.83%	0.96%	-43.73%	-23.16%	-79.46%
Return on Invested Capital (ROIC)	-365.6%	-717.35%	-606.04%	-1016.06%	-337.49%	-99.43%	0.24%	-62.37%	-108.72%	-273.48%
Gross Margin	-	-196.29%	32.85%	64.99%	2.24%	43.65%	87.18%	-393.65%	71.78%	-417.09%
Net Margin	-	-9571.91%	-1209.56%	-130.5%	-481.62%	-94.09%	1.52%	-5660.54%	-64.05%	-3225.05%
Debt / Equity	-	-	1.39x	0.01x	0.89x	0.76x	0.08x	0.09x	0.11x	0.23x
Interest Coverage	-	-450.65x	-56.52x	-156.37x	-104.53x	-164.68x	1.76x	-502.85x	-751.20x	-1014.76x
FCF Conversion	0.78x	0.69x	0.86x	0.19x	0.51x	0.77x	10.55x	0.81x	0.39x	0.85x
Revenue Growth	-	-	532.21%	897.75%	-51.59%	164.75%	154.86%	-98.09%	3565.22%	-95.3%

Revenue by Geography

	2017	2018	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	15.01M	174K	10.84M	484K
UNITED STATES Growth	-	-	-	-	-98.84%	6129.31%	-95.53%
ISRAEL	-	-	-	-	-	5K	31K
ISRAEL Growth	-	-	-	-	-	-	520.00%
CANADA	-	-	-	-	-	87K	-
CANADA Growth	-	-	-	-	-	-	-
Europe	-	-	369K	628K	125K	-	-
Europe Growth	-	-	-	70.19%	-80.10%	-	-
TotalMember	-	-	6.14M	15.64M	-	-	-
TotalMember Growth	-	-	-	154.86%	-	-	-
United States And Canada	-	17.51M	-	-	-	-	-
United States And Canada Growth	-	-	-	-	-	-	-
Europe Country	-	523K	-	-	-	-	-
Europe Country Growth	-	-	-	-	-	-	-
European	866K	-	-	-	-	-	-
European Growth	-	-	-	-	-	-	-
United Satetes And Canada	802K	-	-	-	-	-	-
United Satetes And Canada Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

CollPlant Biotechnologies Ltd. (CLGN) reported $2.5M in revenue for fiscal year 2024.

CollPlant Biotechnologies Ltd. (CLGN) saw revenue decline by 95.3% over the past year.

CollPlant Biotechnologies Ltd. (CLGN) reported a net loss of $12.2M for fiscal year 2024.

Dividend & Returns

CollPlant Biotechnologies Ltd. (CLGN) has a return on equity (ROE) of -79.5%. Negative ROE indicates the company is unprofitable.

CollPlant Biotechnologies Ltd. (CLGN) had negative free cash flow of $10.0M in fiscal year 2024, likely due to heavy capital investments.